Investors Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development
On 8 November 2017, we announced that Dr Hal Barron has been appointed Chief Scientific Officer and President, R&D. He has also been appointed as an Executive Director to the GSK Board.
Dr Barron will assume his new role and join the Board on 1 January 2018.